EEF2K and cancer: Hence, ethyl 1‐(2‐(3,4‐dimethylphenyl)−4‐(3‐fluorobenzyl)−3,5‐dioxo‐2,3,4,5‐tetrahydro‐1,2,4‐triazine‐6‐carbonyl)piperidine‐3‐carboxylate (L15, also named as compound C1), as the most potent eEF2K modulator, was selected to further investigate its mode of action and potential anti‐cancer activity.